Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Clinical trial NCT06824701 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06824701
- Sponsor
- University of Utah
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-12
- Primary completion
- 2032-01-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.